Henry Schein, Inc. $HSIC Position Trimmed by Gabelli Funds LLC

Gabelli Funds LLC decreased its holdings in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 4.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 289,536 shares of the company’s stock after selling 13,500 shares during the period. Gabelli Funds LLC’s holdings in Henry Schein were worth $21,883,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. CYBER HORNET ETFs LLC bought a new stake in Henry Schein during the second quarter valued at $25,000. MUFG Securities EMEA plc bought a new stake in Henry Schein during the second quarter valued at $27,000. Flagship Harbor Advisors LLC bought a new stake in Henry Schein during the fourth quarter valued at $30,000. Steph & Co. bought a new stake in Henry Schein during the fourth quarter valued at $52,000. Finally, Tema Etfs LLC bought a new stake in Henry Schein during the fourth quarter valued at $56,000. Institutional investors own 96.62% of the company’s stock.

Wall Street Analysts Forecast Growth

HSIC has been the subject of several recent research reports. Weiss Ratings reiterated a “hold (c+)” rating on shares of Henry Schein in a research note on Monday, May 4th. Barrington Research set a $97.00 price target on shares of Henry Schein and gave the stock an “outperform” rating in a research report on Wednesday, February 25th. Wall Street Zen lowered shares of Henry Schein from a “strong-buy” rating to a “buy” rating in a research report on Sunday, April 26th. Leerink Partners restated a “market perform” rating on shares of Henry Schein in a research report on Monday, March 9th. Finally, JPMorgan Chase & Co. upped their price target on shares of Henry Schein from $78.00 to $92.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 25th. Six analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $86.83.

Henry Schein Trading Down 0.0%

Shares of HSIC stock opened at $72.69 on Tuesday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.75 and a current ratio of 1.36. Henry Schein, Inc. has a 1 year low of $61.94 and a 1 year high of $89.29. The stock has a fifty day moving average of $74.64 and a two-hundred day moving average of $75.41. The firm has a market capitalization of $8.28 billion, a PE ratio of 21.96, a price-to-earnings-growth ratio of 1.82 and a beta of 0.82.

Henry Schein (NASDAQ:HSIC) last announced its quarterly earnings results on Tuesday, May 5th. The company reported $1.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.20 by $0.12. Henry Schein had a return on equity of 15.44% and a net margin of 2.95%.The company had revenue of $3.37 billion during the quarter, compared to analyst estimates of $3.34 billion. During the same quarter in the previous year, the firm posted $1.15 EPS. The firm’s quarterly revenue was up 6.3% on a year-over-year basis. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. As a group, research analysts expect that Henry Schein, Inc. will post 5.31 EPS for the current year.

Insider Transactions at Henry Schein

In related news, EVP Mark E. Mlotek sold 5,925 shares of the stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $80.80, for a total value of $478,740.00. Following the completion of the transaction, the executive vice president owned 80,554 shares in the company, valued at $6,508,763.20. This represents a 6.85% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director William K. Daniel acquired 10,000 shares of Henry Schein stock in a transaction dated Monday, May 11th. The shares were acquired at an average price of $69.19 per share, with a total value of $691,900.00. Following the transaction, the director owned 20,000 shares in the company, valued at approximately $1,383,800. This represents a 100.00% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have sold a total of 105,911 shares of company stock worth $8,574,982 over the last ninety days. Insiders own 0.89% of the company’s stock.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.